Sponsor study identifier
interventional
436
1 country
1
Study Start
May 1, 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to compare the survival outcomes between hepatic resection and transarterial lipiodol chemoembolization (TACE) used as the initial treatment in patients with Resectable Hepatocellular Carcinoma Beyond Milan Criteria.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 1, 2014
Date type not reportedThis date has not been verified as actual or estimated.
May 13, 2014
Actual (reported)May 15, 2014
Actual (reported)August 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
August 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
overall survival time
5 years
disease free survival
5 years
Number of Adverse Events
30 days
patients received immediate surgical hepatic resection
patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
patients received immediate surgical resection.
Cancer Center Sun Yat-sen University
Guangzhou, Guangdong, 510060, China
Ming Shi, MD
Sun Yat-sen University
First Submitted
May 13, 2014
First Posted
May 15, 2014
Study Start
May 1, 2014
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
August 2020
Estimated (date passed)Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
August 2020
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
August 2, 2018
Record last verified: 2018-07
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: